Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
| ▸ | HTR7 | P34969 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309349 | 0.89 | PIK3CG (0.42) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL26806587 | 0.84 | TSHR (0.40) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL24310735 | 0.84 | PIK3CD (0.39) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL24309239 | 0.83 | CCNT1 (0.40) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL26651235 | 0.83 | PIK3CG (0.38) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL29567131 | 0.83 | PIK3CG (0.38) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL24310345 | 0.83 | TSHR (0.43) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL29566612 | 0.83 | TSHR (0.43) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL26806584 | 0.83 | EGFR (0.41) | TSHREGFRFGFR1KDRSMN1; SMN2 | |
| SCHEMBL26806579 | 0.82 | TSHR (0.38) | TSHREGFRFGFR1KDRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TSHR 1755/4885EGFR 818/4885FGFR1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.